Skip to content
AnalystLens

Medpace Holdings 8-K Report, Financial Results (Jul 22, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 22, 2026
Period End
July 22, 2026
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Change in control8-K · Jun ’17Jun ’17
  2. Leadership change8-K · May ’19May ’19
  3. Leadership change8-K · Jul ’21Jul ’21
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 8-K filed July 22, 2026. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported second quarter 2026 results in a press release furnished as Exhibit 99.1 to this Form 8-K.

Revenue was $707.3 milliona, up 17.2% from $603.3 million a year earlier, and GAAP net income was $121.4 million, or $4.25 per diluted share, versus $90.3 million, or $3.10 per diluted share, in the prior-year quarter. EBITDA was $153.4 million, up 17.6%, with an EBITDA margin of 21.7%. Net new business awards were $795.7 million, up 28.2%, for a net book-to-bill ratio of 1.13x, and backlog as of June 30, 2026 rose 4.9% to $3,014.2 million.

For the six months ended June 30, 2026, revenue was $1,413.9 millionb, up 21.7% on a reported basis, and GAAP net income was $245.2 million, or $8.53 per diluted share. The company ended the quarter with $502.7 million in cash and cash equivalents, generated $162.0 million in operating cash flow in the second quarter, and repurchased 705,616 shares for $294.7 million, leaving $527.0 million under its share repurchase program. The company forecasts full-year 2026 revenue of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion.

It guides to GAAP net income of $494.0 million to $514.0 millionc, diluted EPS of $17.25 to $17.95, and EBITDA of $618.0 million to $642.0 million. Guidance assumes a tax rate of 19.0% to 19.5% and 28.6 million diluted weighted average shares, and excludes any share repurchases after June 30, 2026.

Management will host a conference call on July 23, 2026 at 9:00 a.m. ET.

Key Highlights

  1. Q2 2026 revenue of $707.3 million, up 17.2% from $603.3 million in Q2 2025
  2. Q2 2026 GAAP diluted EPS of $4.25, versus $3.10 in Q2 2025; net income margin of 17.2% versus 15.0%
  3. Net new business awards of $795.7 million (up 28.2%) produced a net book-to-bill ratio of 1.13x
  4. Backlog of $3,014.2 million at June 30, 2026, up 4.9% from $2,873.6 million a year earlier
  5. EBITDA of $153.4 million in Q2 2026 (21.7% margin), up 17.6% from $130.5 million
  6. Repurchased 705,616 shares for $294.7 million in Q2 2026; $527.0 million remains under the authorization
  7. 2026 guidance: revenue of $2.805 billion to $2.885 billion, GAAP diluted EPS of $17.25 to $17.95, and EBITDA of $618.0 million to $642.0 million

Frequently Asked Questions

  1. How did Medpace perform in the second quarter of 2026?

    Revenue rose 17.2% to $707.3 million, GAAP net income was $121.4 million ($4.25 per diluted share), and EBITDA increased 17.6% to $153.4 million, or 21.7% of revenue. On a constant currency basis, revenue grew 17.2% and EBITDA grew 17.8%.

  2. What do the new business awards and backlog indicate?

    Net new business awards were $795.7 million in Q2 2026, up 28.2% from $620.5 million, resulting in a net book-to-bill ratio of 1.13x. Backlog as of June 30, 2026 was $3,014.2 million, up 4.9% from $2,873.6 million a year earlier. The company calculates the book-to-bill ratio by dividing net new business awards by revenue.

  3. What is Medpace's full-year 2026 outlook?

    Medpace forecasts 2026 revenue of $2.805 billion to $2.885 billion, growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion. It expects GAAP net income of $494.0 million to $514.0 million, diluted EPS of $17.25 to $17.95, and EBITDA of $618.0 million to $642.0 million. The guidance assumes a 19.0% to 19.5% tax rate and 28.6 million diluted weighted average shares, and does not include share repurchases after June 30, 2026.

  4. How is Medpace returning capital to shareholders and what is its liquidity position?

    In Q2 2026 Medpace repurchased 705,616 shares for $294.7 million and had $527.0 million remaining under its share repurchase program as of June 30, 2026. Cash and cash equivalents were $502.7 million at quarter-end, and operating cash flow was $162.0 million in Q2 2026.

  5. What is the timing of the earnings call and where can investors find more information?

    Medpace will host a conference call at 9:00 a.m. ET on Thursday, July 23, 2026. A webcast replay will be available on the Investors section of medpace.com about one hour after the call ends, and a supplemental slide presentation will be posted before the call begins.